Skip to main content

Excessive Bleeding During Surgery

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Dilon Technologies
Dilon TechnologiesVA - Newport News
1 program
1
Hemoblast Bellows applicationPhase 41 trial
Active Trials
NCT06511778Recruiting60Est. Sep 2026
Grifols
GrifolsNEW YORK, NY
1 program
Fibrin Sealant GrifolsPHASE_31 trial
Active Trials
NCT03461406Completed186Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Dilon TechnologiesHemoblast Bellows application
GrifolsFibrin Sealant Grifols

Clinical Trials (2)

Total enrollment: 246 patients across 2 trials

NCT06511778Dilon TechnologiesHemoblast Bellows application

sTErnAl heMostasiS Trial

Start: Oct 2024Est. completion: Sep 202660 patients
Phase 4Recruiting
NCT03461406GrifolsFibrin Sealant Grifols

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

Start: Jan 2019Est. completion: May 2022186 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 246 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.